

# SAFETY DATA SHEET

## Polyclonal Rabbit Antibody Solution

### Section 1. Identification

#### 1.1 Product identifier

- Product name** : Polyclonal Rabbit Antibody Solution
- Part no.** : A0001, A0002, A0008, A0011, A0012, A0021, A0022, A0024, A0030, A0033, A0040, A0061, A0062, A0063, A0065, A0072, A0077, A0080, A0082, A0092, A0093, A0094, A0099, A0100, A0101, A0115, A0118, A0133, A0136, A0146, A0186, A0190, A0191, A0192, A0193, A0194, A0206, A0225, A0230, A0231, A0245, A0251, A0253, A0262, A0296, A0301, A0302, A0370, A0373, A0384, A0398, A0423, A0424, A0425, A0426, A0451, A0452, A0485, A0562, A0568, A0570, A0576, A4502, B0114, B0357, B0471, O9127, OA016, OA044, OA500, OA521, OA522, OA529, OA541, OA561, OA854, OA855, OA995, OA997, Q0023, Q0102, Q0121, Q0122, Q0149, Q0326, Q0327, Q0328, Q0329, Q0330, Q0331, Q0332, Q0333, Q0362, Q0363, Q0367, Q0368, Q0369, Q0495, Q0496, Q0497, Q0498, Q0499, X0903, X0936, Z5116
- Validation date** : 12/5/2022

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

- Identified uses** :  Laboratory use
- Container type: Bottle (50 ml to 3 L)
- A0001 // Polyclonal Rabbit Anti-Human Albumin // 0.05 - 3 L
- A0002 // Polyclonal Rabbit Anti-Human Prealbumin // 0.05 - 3 L
- A0008 // Polyclonal Rabbit Anti-Human Alpha-1-Fetoprotein // 0.05 - 3 L
- A0011 // Polyclonal Rabbit Anti-Human Orosomucoid // 0.05 - 3 L
- A0012 // Polyclonal Rabbit Anti-Human Alpha-1-Antitrypsin // 0.05 - 3 L
- A0021 // Polyclonal Rabbit Anti-Human Gc-Globulin // 0.05 - 3 L
- A0022 // Polyclonal Rabbit Anti-Human Alpha-1-Antichymotrypsin // 0.05 - 3 L
- A0024 // Polyclonal Rabbit Anti-Human Tau // 0.05 - 3 L
- A0030 // Polyclonal Rabbit Anti-Human Haptoglobin // 0.05 - 3 L
- A0033 // Polyclonal Rabbit Anti-Human Alpha-2-Macroglobulin // 0.05 - 3 L
- A0040 // Polyclonal Rabbit Anti-Human Retinol-Binding-Protein (RBP) // 0.05 - 3 L
- A0061 // Polyclonal Rabbit Anti-Human Transferrin // 0.05 - 3 L
- A0062 // Polyclonal Rabbit Anti-Human C3c Complement // 0.05 - 3 L
- A0063 // Polyclonal Rabbit Anti-Human C3d Complement // 0.05 - 3 L
- A0065 // Polyclonal Rabbit Anti-Human C4c Complement // 0.05 - 3 L
- A0072 // Polyclonal Rabbit Anti-Human Beta-2-Microglobulin // 0.05 - 3 L
- A0077 // Polyclonal Rabbit Anti-Human Apolipoprotein E // 0.05 - 3 L
- A0080 // Polyclonal Rabbit Anti-Human Fibrinogen // 0.05 - 3 L
- A0082 // Polyclonal Rabbit Anti-Human Von Willebrand Factor // 0.05 - 3 L
- A0092 // Polyclonal Rabbit Anti-Human IgA, (Specific for Alpha-Chains) // 0.05 - 3 L
- A0093 // Polyclonal Rabbit Anti-Human IgD, (Specific for Delta-Chains) // 0.05 - 3 L
- A0094 // Polyclonal Rabbit Anti-Human IgE, (Specific for Epsilon-Chains) // 0.05 - 3 L
- A0099 // Polyclonal Rabbit Anti-Human Lysozyme // 0.05 - 3 L
- A0100 // Polyclonal Rabbit Anti-Human Kappa Free Light Chains // 0.05 - 3 L
- A0101 // Polyclonal Rabbit Anti-Human Lambda Free Light Chains // 0.05 - 3 L
- A0115 // Polyclonal Rabbit Anti-Human Carcinoembryonic Antigen (CEA) // 0.05 - 3 L
- A0118 // Polyclonal Rabbit Anti-Human Hemoglobin // 0.05 - 3 L
- A0133 // Polyclonal Rabbit Anti-Human Ferritin // 0.05 - 3 L
- A0136 // Polyclonal Rabbit Anti-Human C1q Complement // 0.05 - 3 L
- A0146 // Polyclonal Rabbit Anti-Human Gelsolin // 0.05 - 3 L
- A0186 // Polyclonal Rabbit Anti-Human Lactoferrin // 0.05 - 3 L
- A0190 // Polyclonal Rabbit Anti-Human Polyclonal Rabbit anti Human IgA, IgG, IgM // 0.05 - 3 L
- A0191 // Polyclonal Rabbit Anti-Human Kappa Light Chains // 20-500 mL
- A0192 // Polyclonal Rabbit Anti-Human Kappa Light Chains // 0.05 - 3 L
- A0193 // Polyclonal Rabbit Anti-Human Lambda Light Chains // 20-30.000 mL
- A0194 // Polyclonal Rabbit Anti-Human Lambda Light Chains // 0.05 - 3 L
- A0206 // Polyclonal Rabbit Anti-Human Serum // 0.05 - 3 L

## Section 1. Identification

A0225 // Polyclonal Rabbit Anti-HumanThrombocyte // 0.05 - 3 L  
A0230 // Polyclonal Rabbit Anti-Human Pregnancy-Associated Plasma Protein A (PAPP-A) // 0.05 - 3 L  
A0231 // Polyclonal Rabbit Anti-Human Human Chorionic Gonadotropin (hCG) // 0.05 - 3 L  
A0245 // Polyclonal Rabbit Anti-Human Fibronectin // 0.05 - 3 L  
A0251 // Polyclonal Rabbit Anti-Human Thyroglobulin // 0.05 - 3 L  
A0253 // Polyclonal Rabbit Anti-Human C1-Inactivator // 0.05 - 3 L  
A0262 // Polyclonal Rabbit Anti-Human IgA, Specific for Alpha-Chains), ELISA pure // 0.05 - 3 L  
A0296 // Polyclonal Rabbit Anti-Human Antithrombin III // 0.05 - 3 L  
A0301 // Polyclonal Rabbit Anti-Human Inter-Alpha-Trypsin inhibitor // 0.05 - 3 L  
A0302 // Polyclonal Rabbit Anti-Human P-Component // 0.05 - 3 L  
A0370 // Polyclonal Rabbit Anti-Human Protein C // 0.05 - 3 L  
A0373 // Polyclonal Rabbit Anti-Human Factor X // 0.05 - 3 L  
A0384 // Polyclonal Rabbit Anti-Human Protein S // 0.05 - 3 L  
A0398 // Polyclonal Rabbit Anti-Human Myeloperoxidase // 0.05 - 3 L  
A0423 // Polyclonal Rabbit Anti-Human IgG, (Specific for Gamma-Chains), ELISA pure // 0.05 - 3 L  
A0424 // Polyclonal Rabbit Anti-Human IgG, (Specific for Gamma-Chains) // 0.05 - 3 L  
A0425 // Polyclonal Rabbit Anti-Human IgM, (Specific for Mu-Chains), ELISA pure // 0.05 - 3 L  
A0426 // Polyclonal Rabbit Anti-Human IgM, (Specific for Mu-Chains) // 0.05 - 3 L  
A0451 // Polyclonal Rabbit Anti-Human Cystatin C // 0.05 - 3 L  
A0452 // Polyclonal Rabbit Anti-Human CD3 // 0.2 mL, 1mL  
A0485 // Polyclonal Rabbit Anti-Human c-erbB-2 Oncoprotein // 0.2 mL  
A0562 // Polyclonal Rabbit Anti-Human Prostate Specific Antigen (PSA) // 0.05 - 3 L  
A0568 // Polyclonal Rabbit Anti-Human Gastrin // 0.05 - 3 L  
A0570 // Polyclonal Rabbit Anti-Human Growth Hormone // 1 mL  
A0576 // Polyclonal Rabbit Anti-Human Calcitonin // 0.05 - 3 L  
B0114 // Polyclonal Rabbit Anti-Herpes Simplex Virus Type 1 // 2 mL, 20-1.000 mL  
B0357 // Polyclonal Rabbit Anti-Escherichia Coli // 20-200 mL  
B0471 // Polyclonal Rabbit Anti-Helicobacter Pylori // 0.2 mL, 1-1200 mL  
O9127 // Polyclonal Rabbit Anti-Human Lambda Free Light Chains // 0.05 - 3 L  
OA016 // Polyclonal Rabbit Anti-Human Kappa Free Light Chains // 0.05 - 3 L  
OA044 // Polyclonal Rabbit Anti-Human Myoglobin // 0.05 - 3 L  
OA500 // Polyclonal Rabbit Anti-Human Albumin (Microalbumin) (RTU) // 0.05 - 3 L  
OA521 // Polyclonal Rabbit Anti-Human Apolipoprotein A-1 (RTU) // 0.05 - 3 L  
OA522 // Polyclonal Rabbit Anti-Human Apolipoprotein B (RTU) // 0.05 - 3 L  
OA529 // Polyclonal Rabbit Anti-HumanRetinol-Binding-Protein (RBP) (RTU) // 0.05 - 3 L  
OA541 // Polyclonal Rabbit Anti-Human C-Reactive Protein, Slow-Reacting Antibody // 0.05 - 3 L  
OA561 // Polyclonal Rabbit Anti-Human NGAL // 0.05 - 3 L  
OA854 // Polyclonal Rabbit Anti-Human Calprotectin // 0.05 - 3 L  
OA855 // Polyclonal Rabbit Anti-Human Troponin I // 0.05 - 3 L  
OA995 // Polyclonal Rabbit Anti-Human NGAL // 0.05 - 5 L  
OA997 // Polyclonal Rabbit Anti-Human SAA // 0.05 - 5 L  
Q0023 // Polyclonal Rabbit Anti-Human Lipoprotein (a) // 0.05 - 3 L  
Q0102 // Polyclonal Rabbit Anti-Human Alpha-2-Macroglobulin // 0.05 - 3 L  
Q0121 // Polyclonal Rabbit Anti-Human Ceruloplasmin // 0.05 - 3 L  
Q0122 // Polyclonal Rabbit Anti-Human Fibrinogen // 0.05 - 3 L  
Q0149 // Polyclonal Rabbit Anti-Human Fibronectin // 0.05 - 3 L  
Q0326 // Polyclonal Rabbit Anti-Human Orosomucoid (Alpha-1-Acid-Glycoprotein) // 0.05 - 3 L  
Q0327 // Polyclonal Rabbit Anti-Human Transferrin RTU // 0.05 - 3 L  
Q0328 // Polyclonal Rabbit Anti-Human Albumin (Microalbumin) // 0.05 - 3 L  
Q0329 // Polyclonal Rabbit Anti-Human C-Reactive Protein // 0.05 - 3 L  
Q0330 // Polyclonal Rabbit Anti-Human Haptoglobin // 0.05 - 3 L  
Q0331 // Polyclonal Rabbit Anti-Human IgG // 0.05 - 3 L  
Q0332 // Polyclonal Rabbit Anti-Human IgA // 0.05 - 3 L

## Section 1. Identification

Q0333 // Polyclonal Rabbit Anti-Human IgM // 0.05 - 3 L  
Q0362 // Polyclonal Rabbit Anti-Human Prealbumin // 0.05 - 3 L  
Q0363 // Polyclonal Rabbit Anti-Human Alpha-1-Antitrypsin // 0.05 - 3 L  
Q0367 // Polyclonal Rabbit Anti-Human Alpha-1-Antichymotrypsin // 0.05 - 3 L  
Q0368 // Polyclonal Rabbit Anti-Human C3c Complement // 0.05 - 3 L  
Q0369 // Polyclonal Rabbit Anti-Human C4c Complement // 0.05 - 3 L  
Q0495 // Polyclonal Rabbit Anti-Human Alpha-1-Microglobulin // 0.05 - 3 L  
Q0496 // Polyclonal Rabbit Anti-Human Apolipoprotein A-1 // 0.05 - 3 L  
Q0497 // Polyclonal Rabbit Anti-Human Apolipoprotein B // 0.05 - 3 L  
Q0498 // Polyclonal Rabbit Anti-Human Kappa Light Chains // 0.05 - 3 L  
Q0499 // Polyclonal Rabbit Anti-Human Lambda Light Chains // 0.05 - 3 L  
X0903 // Negative Control, Rabbit Immunoglobulin Fraction (Normal) // 0.05 - 3 L  
X0936 // Negative Control, Rabbit Immunoglobulin Fraction (Solid-Phase Absorbed) // 0.05 - 3 L  
Z5116 // Polyclonal Rabbit Anti-PGP 9.5 // 1 mL  
Reference number: SDS345

### 1.3 Details of the supplier of the safety data sheet

#### **Supplier/Manufacturer**

: Agilent Technologies, Inc.  
5301 Stevens Creek Blvd  
Santa Clara, CA 95051, USA  
Tel: +1 800 227 9770

Agilent Technologies Singapore (International) Pte Ltd.  
No. 1 Yishun Avenue 7  
Singapore, 768923  
Tel. (65) 6276 2622

Agilent Technologies Denmark ApS  
Produktionsvej 42  
2600 Glostrup,  
Denmark  
Tel. +45 44 85 95 00

www.Agilent.com

**e-mail address of person responsible for this SDS** : SDS@Agilent.com

### 1.4 Emergency telephone number

**In case of emergency** : CHEMTREC®: 1-800-424-9300

## Section 2. Hazards identification

### 2.1 Classification of the substance or mixture

**OSHA/HCS status** : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

### Classification of the substance or mixture

Not classified.

### 2.2 GHS label elements

**Signal word** : No signal word.  
**Hazard statements** : No known significant effects or critical hazards.

## Section 2. Hazards identification

### Precautionary statements

- Prevention** : Not applicable.  
**Response** : Not applicable.  
**Storage** : Not applicable.  
**Disposal** : Not applicable.

### 2.3 Other hazards

- Hazards not otherwise classified** : None known.

## Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

## Section 4. First aid measures

### 4.1 Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

### 4.2 Most important symptoms/effects, acute and delayed

#### Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.  
**Inhalation** : No known significant effects or critical hazards.  
**Skin contact** : No known significant effects or critical hazards.  
**Ingestion** : No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

- Eye contact** : No specific data.  
**Inhalation** : No specific data.  
**Skin contact** : No specific data.  
**Ingestion** : No specific data.

### 4.3 Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

## Section 5. Fire-fighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

### 5.2 Special hazards arising from the substance or mixture

- Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous thermal decomposition products** : Decomposition products may include the following materials:  
 carbon dioxide  
 carbon monoxide  
 nitrogen oxides  
 phosphorus oxides

### 5.3 Advice for firefighters

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- 6.2 Environmental precautions** : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### 6.3 Methods and materials for containment and cleaning up

- Methods for cleaning up** : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

## Section 7. Handling and storage

### 7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

## Section 7. Handling and storage

### 7.2 Conditions for safe storage, including any incompatibilities

: Specific storage conditions: Please consult the label.  
 Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s)

**Recommendations** : Industrial applications, Professional applications.

**Industrial sector specific solutions** : Not available.

## Section 8. Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational exposure limits

Ingredient name	Exposure limits
None.	

#### Biological exposure indices

No exposure indices known.

### 8.2 Exposure controls

#### Appropriate engineering controls

: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

#### Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

#### Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

#### Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

#### Skin protection

##### Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

##### Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

##### Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

## Section 8. Exposure controls/personal protection

- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### Appearance

- Physical state** : Liquid.  
**Color** : Not available.  
**Odor** : Not available.  
**Odor threshold** : Not available.  
**pH** : 6.5 to 8.5  
**Melting point/freezing point** : Not available.  
**Boiling point, initial boiling point, and boiling range** : Not available.  
**Flash point** : Not available.  
**Evaporation rate** : Not available.  
**Flammability** : Not applicable.  
**Lower and upper explosion limit/flammability limit** : Not available.  
**Vapor pressure** :

Ingredient name	Vapor Pressure at 20°C			Vapor pressure at 50°C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
Water	23.8	3.2		92.258	12.3	

- Relative vapor density** : Not available.

- Relative density** : Not available.

Media	Result
Water	Soluble

- Miscible with water** : Yes.

- Partition coefficient: n-octanol/water** : Not applicable.

- Auto-ignition temperature** : Not available.

- Decomposition temperature** : Not available.

- Viscosity** : Not available.

### Particle characteristics

- Median particle size** : Not applicable.

## Section 10. Stability and reactivity

- 10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.

- 10.2 Chemical stability** : The product is stable.

- 10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.

## Section 10. Stability and reactivity

**10.4 Conditions to avoid** : No specific data.

**10.5 Incompatible materials** : May react or be incompatible with oxidizing materials.

**10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### 11.1 Information on toxicological effects

#### Acute toxicity

Not available.

#### Irritation/Corrosion

Not available.

#### Sensitization

Not available.

#### Mutagenicity

**Conclusion/Summary** : Not available.

#### Carcinogenicity

**Conclusion/Summary** : Not available.

#### Reproductive toxicity

**Conclusion/Summary** : Not available.

#### Teratogenicity

**Conclusion/Summary** : Not available.

#### Specific target organ toxicity (single exposure)

Not available.

#### Specific target organ toxicity (repeated exposure)

Not available.

#### Aspiration hazard

Not available.

**Information on the likely routes of exposure** : Not available.

### Potential acute health effects

**Eye contact** : No known significant effects or critical hazards.

**Inhalation** : No known significant effects or critical hazards.

**Skin contact** : No known significant effects or critical hazards.

**Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : No specific data.

**Inhalation** : No specific data.

**Skin contact** : No specific data.

**Ingestion** : No specific data.

### Delayed and immediate effects and also chronic effects from short and long term exposure



## Section 11. Toxicological information

### Short term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Long term exposure

**Potential immediate effects** : Not available.

**Potential delayed effects** : Not available.

### Potential chronic health effects

**General** : No known significant effects or critical hazards.

**Carcinogenicity** : No known significant effects or critical hazards.

**Mutagenicity** : No known significant effects or critical hazards.

**Reproductive toxicity** : No known significant effects or critical hazards.

### Numerical measures of toxicity

#### Acute toxicity estimates

N/A

## Section 12. Ecological information

### 12.1 Toxicity

Not available.

### 12.2 Persistence and degradability

Not available.

### 12.3 Bioaccumulative potential

Not available.

### 12.4 Mobility in soil

**Soil/water partition coefficient ( $K_{oc}$ )** : Not available.

**12.5 Other adverse effects** : No known significant effects or critical hazards.

## Section 13. Disposal considerations

### 13.1 Waste treatment methods

**Disposal methods** : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

## Section 13. Disposal considerations

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

## Section 14. Transport information

**DOT / TDG / Mexico / IMDG / IATA** : Not regulated.

**Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to IMO instruments** : Not available.

## Section 15. Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

**U.S. Federal regulations** : TSCA 8(a) CDR Exempt/Partial exemption: Not determined

**Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs)** : Not listed

**Clean Air Act Section 602 Class I Substances** : Not listed

**Clean Air Act Section 602 Class II Substances** : Not listed

**DEA List I Chemicals (Precursor Chemicals)** : Not listed

**DEA List II Chemicals (Essential Chemicals)** : Not listed

### SARA 302/304

#### Composition/information on ingredients

Name	%	EHS	SARA 302 TPQ		SARA 304 RQ	
			(lbs)	(gallons)	(lbs)	(gallons)
Sodium azide	<0.1	Yes.	500	-	1000	-

**SARA 304 RQ** : 1025641 lbs / 465641 kg

### SARA 311/312

**Classification** : Not applicable.

#### Composition/information on ingredients

No products were found.

### State regulations

## Section 15. Regulatory information

- Massachusetts** : None of the components are listed.  
**New York** : None of the components are listed.  
**New Jersey** : None of the components are listed.  
**Pennsylvania** : None of the components are listed.  
**California Prop. 65**

This product does not require a Safe Harbor warning under California Prop. 65.

### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### Montreal Protocol

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

### Inventory list

- Australia** : Not determined.  
**Canada** : Not determined.  
**China** : All components are listed or exempted.  
**Eurasian Economic Union** : **Russian Federation inventory**: Not determined.  
**Japan** : **Japan inventory (CSCL)**: Not determined.  
**Japan inventory (ISHL)**: All components are listed or exempted.  
**New Zealand** : Not determined.  
**Philippines** : Not determined.  
**Republic of Korea** : Not determined.  
**Taiwan** : All components are listed or exempted.  
**Thailand** : Not determined.  
**Turkey** : Not determined.  
**United States** : All components are active or exempted.  
**Viet Nam** : Not determined.

## Section 16. Other information

### Procedure used to derive the classification

Classification	Justification
Not classified.	

### History

- Date of issue** : 12/05/2022  
**Date of previous issue** : 03/08/2022  
**Version** : 7.1

## Section 16. Other information

### Key to abbreviations

- : ATE = Acute Toxicity Estimate
- BCF = Bioconcentration Factor
- GHS = Globally Harmonized System of Classification and Labelling of Chemicals
- IATA = International Air Transport Association
- IBC = Intermediate Bulk Container
- IMDG = International Maritime Dangerous Goods
- LogPow = logarithm of the octanol/water partition coefficient
- MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
- N/A = Not available
- UN = United Nations

✔ Indicates information that has changed from previously issued version.

### Notice to reader

**Disclaimer:** The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.